Literature DB >> 12512188

Fungal infections in nontransplant patients with hematologic malignancies.

Brahm H Segal1, Eric J Bow, Francisco Menichetti.   

Abstract

Fungal infections are a major cause of morbidity and mortality in patients with hematologic malignancies. Candida and Aspergillus species are the most important opportunistic fungal pathogens in this patient population. Dimorphic fungi can cause serious infection in immunocompetent persons, but infection is more likely to be disseminated in patients with compromised cell-mediated immunity. Cryptococcus neoformans and Pneumosystis carinii typically cause infections in persons with severe T-cell suppression. The frequency of rare pathogenic fungi commonly resistant to amphotericin B has significantly increased over the past 20 years among patients with hematologic malignancies. Examples of such emerging pathogens include Trichosporon, Fusarium, and Scedosporium species, and dark-walled molds. This article reviews the epidemiology, clinical manifestations, diagnostic evaluation, and treatment of the major fungal pathogens in nontransplant patients with hematologic malignancies.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12512188     DOI: 10.1016/s0891-5520(02)00043-0

Source DB:  PubMed          Journal:  Infect Dis Clin North Am        ISSN: 0891-5520            Impact factor:   5.982


  12 in total

Review 1.  Severe rhinosinusitis.

Authors:  Rosemary Hallett; Stanley M Naguwa
Journal:  Clin Rev Allergy Immunol       Date:  2003-10       Impact factor: 8.667

Review 2.  Geotrichum capitatum septicemia: case report and review of the literature.

Authors:  H Trabelsi; S Néji; L Gargouri; H Sellami; R Guidara; F Cheikhrouhou; H Bellaaj; F Makni; M Elloumi; A Ayadi
Journal:  Mycopathologia       Date:  2015-02-14       Impact factor: 2.574

Review 3.  Fungal Pneumonia in Patients with Hematologic Malignancy and Hematopoietic Stem Cell Transplantation.

Authors:  Alisha Y Young; Miguel M Leiva Juarez; Scott E Evans
Journal:  Clin Chest Med       Date:  2017-05-31       Impact factor: 2.878

Review 4.  [Therapy of severe fungal infections].

Authors:  M Battegay; U Flückiger
Journal:  Internist (Berl)       Date:  2003-12       Impact factor: 0.743

5.  Antifungal activities of posaconazole and granulocyte-macrophage colony-stimulating factor ex vivo and in mice with disseminated infection due to Scedosporium prolificans.

Authors:  M Simitsopoulou; C Gil-Lamaignere; N Avramidis; A Maloukou; S Lekkas; E Havlova; L Kourounaki; D Loebenberg; E Roilides
Journal:  Antimicrob Agents Chemother       Date:  2004-10       Impact factor: 5.191

6.  Imaging features of fungal infection in immuno-suppressed patients in a local ward outbreak.

Authors:  S Ahmad Sarji; Wa Wan Abdullah; Ml Wastie
Journal:  Biomed Imaging Interv J       Date:  2006-04-01

7.  Therapeutic efficacy of a conjugate vaccine containing a peptide mimotope of cryptococcal capsular polysaccharide glucuronoxylomannan.

Authors:  Kausik Datta; Andrew Lees; Liise-anne Pirofski
Journal:  Clin Vaccine Immunol       Date:  2008-06-04

8.  Geotrichum capitatum septicemia in patients with acute myeloid leukemia. Report of three cases.

Authors:  Fatma Saghrouni; Jihene Ben Abdeljelil; Yosra Ben Youssef; Nour Ben Abdeljelil; Soukeina Gheith; Akila Fathallah; Moncef Ben Said
Journal:  Med Mycol Case Rep       Date:  2012-09-26

9.  Immune Cell Paracrine Signaling Drives the Neutrophil Response to A. fumigatus in an Infection-on-a-Chip Model.

Authors:  Laurel E Hind; Morgan A Giese; Taylor J Schoen; David J Beebe; Nancy Keller; Anna Huttenlocher
Journal:  Cell Mol Bioeng       Date:  2020-10-13       Impact factor: 2.321

10.  Detection of Aspergillus flavus and A. fumigatus in Bronchoalveolar Lavage Specimens of Hematopoietic Stem Cell Transplants and Hematological Malignancies Patients by Real-Time Polymerase Chain Reaction, Nested PCR and Mycological Assays.

Authors:  Hossein Zarrinfar; Hossein Mirhendi; Abdolmajid Fata; Hossein Khodadadi; Parivash Kordbacheh
Journal:  Jundishapur J Microbiol       Date:  2014-12-17       Impact factor: 0.747

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.